Pacbio plans public offering of common stock
MENLO PARK, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences (NASDAQ:PACB) (the “Company”) today announced that it has priced its previously announced underwritten public offering of 12,500,000 shares of its common stock at a price to the public of $2.40 per share. The offering is expected to close on or about February 15, 2018 subject to satisfaction of customary closing conditions. Pacific Biosciences also granted the underwriters a 30-day option to purchase up to an A public offering is a corporation’s sale of stock shares to the public. The effect of a public offering on a stock price depends on whether the additional shares are newly created or are existing, privately owned shares held by company insiders. Headquartered in Menlo Park, CA, Pacific Biosciences of California, Inc. PACB recently announced that it has priced its underwritten public offering of 15.4 million shares of its common stock. The aforementioned stock was priced to the public for $3.10 per share. The offering is expected to close on Jun 20, 2017. NEW YORK (GenomeWeb) – Pacific Biosciences announced today that it plans to raise gross proceeds of $30 million in a planned public offering of 12.5 million shares of common stock at $2.40 per share. PacBio will also grant the underwriters a 30-day option to purchase up to almost an additional 1,875,000 shares of its common stock sold in the offering. MENLO PARK, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”) today announced that it has priced its previously announced underwritten public offering of 14,117,647 shares of its common stock at a price to the public of $4.25 per share. Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock MENLO PARK, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:
Headquartered in Menlo Park, CA, Pacific Biosciences of California, Inc. PACB recently announced that it has priced its underwritten public offering of 15.4 million shares of its common stock. The aforementioned stock was priced to the public for $3.10 per share. The offering is expected to close on Jun 20, 2017.
Dec 18, 2019 Shares of Pacific Biosciences of California Inc. tumbled 3% in morning trading the day after the Federal Trade Commission announced plans to Based on 3 Wall Street analysts offering stock ratings for Pacific Biosciences in the last 3 months (by analysts ranked 0 to 5 stars). All Analysts. Top Analysts Jan 3, 2020 With in-dining restrictions, these San Diego eateries are offering Its technology has also powered popular DNA-testing services such as Illumina, a $47 billion public company, is already a mammoth in the DNA sequencing space. At the market's close on Friday, Illumina's stock (Nasdaq: ILMN) had Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock Monday, September 10, 2018 MENLO PARK, Calif. , Sept. 10, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. MENLO PARK, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced that it intends to offer and sell shares of its common stock in an NEW YORK (GenomeWeb) – Pacific Biosciences said after the close of the market on Monday that it plans to sell shares of its common stock in a public offering. The Menlo Park, California-based maker of sequencing platforms did not disclose the number of shares it planned to sell or how much money it expects to raise. Pacific Biosciences of California, Inc. PACB, -24.26% today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Pacific Biosciences also
MENLO PARK, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”) today announced that it has priced its previously announced underwritten public offering of 14,117,647 shares of its common stock at a price to the public of $4.25 per share.
MENLO PARK, Calif., June 15, 2017 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ:PACB) (the “Company”) today announced that it has priced its previously announced underwritten public offering of 15,419,354 shares of its common stock at a price to the public of $3.10 per share.
MENLO PARK, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences (NASDAQ:PACB) (the “Company”) today announced that it has priced its previously announced underwritten public offering of 12,500,000 shares of its common stock at a price to the public of $2.40 per share. The offering is expected to close on or about February 15, 2018 subject to satisfaction of customary closing conditions. Pacific Biosciences also granted the underwriters a 30-day option to purchase up to an
MENLO PARK, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ:PACB) (the “Company”) today announced that it has priced its previously announced underwritten public offering of 12,500,000 shares of its common stock at a price to the public of $2.40 per share. MENLO PARK, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. MENLO PARK, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences (NASDAQ:PACB) (the “Company”) today announced that it has priced its previously announced underwritten public offering of 12,500,000 shares of its common stock at a price to the public of $2.40 per share. The offering is expected to close on or about February 15, 2018 subject to satisfaction of customary closing conditions. Pacific Biosciences also granted the underwriters a 30-day option to purchase up to an A public offering is a corporation’s sale of stock shares to the public. The effect of a public offering on a stock price depends on whether the additional shares are newly created or are existing, privately owned shares held by company insiders. Headquartered in Menlo Park, CA, Pacific Biosciences of California, Inc. PACB recently announced that it has priced its underwritten public offering of 15.4 million shares of its common stock. The aforementioned stock was priced to the public for $3.10 per share. The offering is expected to close on Jun 20, 2017. NEW YORK (GenomeWeb) – Pacific Biosciences announced today that it plans to raise gross proceeds of $30 million in a planned public offering of 12.5 million shares of common stock at $2.40 per share. PacBio will also grant the underwriters a 30-day option to purchase up to almost an additional 1,875,000 shares of its common stock sold in the offering.
NEW YORK (GenomeWeb) – Pacific Biosciences said after the close of the market on Monday that it plans to sell shares of its common stock in a public offering. The Menlo Park, California-based maker of sequencing platforms did not disclose the number of shares it planned to sell or how much money it expects to raise.
Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock Monday, September 10, 2018 MENLO PARK, Calif. , Sept. 10, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. MENLO PARK, Calif., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced that it intends to offer and sell shares of its common stock in an NEW YORK (GenomeWeb) – Pacific Biosciences said after the close of the market on Monday that it plans to sell shares of its common stock in a public offering. The Menlo Park, California-based maker of sequencing platforms did not disclose the number of shares it planned to sell or how much money it expects to raise. Pacific Biosciences of California, Inc. PACB, -24.26% today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Pacific Biosciences also NEW YORK (GenomeWeb) – Pacific Biosciences announced today that it plans to raise gross proceeds of $30 million in a planned public offering of 12.5 million shares of common stock at $2.40 per share. PacBio will also grant the underwriters a 30-day option to purchase up to almost an additional 1,875,000 shares of its common stock sold in the offering. MENLO PARK, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”) today announced that it has priced its previously announced underwritten public offering of 14,117,647 shares of its common stock at a price to the public of $4.25 per share. MENLO PARK, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ:PACB) (the “Company”) today announced that it has priced its previously announced underwritten public offering of 12,500,000 shares of its common stock at a price to the public of $2.40 per share.
NEW YORK (GenomeWeb) – Pacific Biosciences said after the close of the market on Monday that it plans to sell shares of its common stock in a public offering. The Menlo Park, California-based maker of sequencing platforms did not disclose the number of shares it planned to sell or how much money it expects to raise. Pacific Biosciences of California, Inc. PACB, -24.26% today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. Pacific Biosciences also NEW YORK (GenomeWeb) – Pacific Biosciences announced today that it plans to raise gross proceeds of $30 million in a planned public offering of 12.5 million shares of common stock at $2.40 per share. PacBio will also grant the underwriters a 30-day option to purchase up to almost an additional 1,875,000 shares of its common stock sold in the offering. MENLO PARK, Calif., Sept. 12, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) (the “Company”) today announced that it has priced its previously announced underwritten public offering of 14,117,647 shares of its common stock at a price to the public of $4.25 per share. MENLO PARK, Calif., Feb. 13, 2018 (GLOBE NEWSWIRE) — Pacific Biosciences of California, Inc. (NASDAQ:PACB) (the “Company”) today announced that it has priced its previously announced underwritten public offering of 12,500,000 shares of its common stock at a price to the public of $2.40 per share.